Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P19440
UPID:
GGT1_HUMAN
Alternative names:
Gamma-glutamyltransferase 1; Gamma-glutamyltranspeptidase 1; Leukotriene-C4 hydrolase
Alternative UPACC:
P19440; Q08247; Q14404; Q8TBS1; Q9UMK1
Background:
Gamma-glutamyltransferase 1 (GGT1), also known as Glutathione hydrolase 1 proenzyme, plays a crucial role in the metabolism of glutathione, breaking down this vital antioxidant to maintain cellular health. It cleaves the gamma-glutamyl bond of glutathione and its conjugates, facilitating the release of free glutamate and the dipeptide cysteinyl-glycine. This process is essential for cellular detoxification and the recycling of glutathione.
Therapeutic significance:
GGT1's involvement in Glutathionuria, a rare metabolic disorder characterized by glutathione presence in urine and associated with intellectual disability and behavioral disturbances, highlights its therapeutic potential. Understanding the role of Gamma-glutamyltransferase 1 could open doors to potential therapeutic strategies for treating Glutathionuria and related metabolic disorders.